Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry

Bone Marrow Transplantation

Volumn 18, Issue 1, 1996, Pages 125-130

  Garaventa, A ^a   Rondelli, R ^b   Lanino, E ^a   Dallorso, S ^a   Dini, G ^a   Bonetti, F ^c   Arrighini, A ^d   Santoro, N ^e   Rossetti, F ^f   Miniero, R ^g   Andolina, M ^h   Amici, A ⁱ   Indolfi, P ^j   Lo Curto, M ^k   Favre, C ^l   Paolucci, P ^b   Pession, A ^b   De Bernardi, B ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h UNIVERSITY OF TRIESTE   (Italy)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^k UNIVERSITY OF PALERMO   (Italy)

^l UNIVERSITY OF PISA   (Italy)

more..

Author keywords

Bone marrow graft; Megatherapy; Neuroblastoma

Indexed keywords

DOXORUBICIN; MELPHALAN; PEPTICHEMIO; TENIPOSIDE; VINCRISTINE;

ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; BONE MARROW RESCUE; CANCER MORTALITY; CELL TRANSPLANTATION; CHILD; CHILDHOOD CANCER; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEUROBLASTOMA; NEWBORN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFECTION; ITALY; LIVER DISEASES; MALE; MELPHALAN; NEUROBLASTOMA; REGISTRIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VINCRISTINE; WHOLE-BODY IRRADIATION;

EID: 9544255700     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. De Bernardi B, Pianca C, Boni L et al. Disseminated neuroblastoma (Stage IV and IV-S) in the first year of life. Cancer 1992; 70: 1625-1633.
2. De Bernardi B, Carli M, Casale F et al. Standard and highdose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies of the Italian Cooperative Group for neuroblastoma. J Clin Oncol 1992; 10: 1870-1878.
3. Lanino E, Parasole R, Garaventa A et al. Treatment of poorrisk neuroblastoma with intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor. In: Freund M, Link H, Schmidt RE, Welte K (eds). Cytokines in Hematopoiesis and AIDS II. Springer-Verlag: Berlin, Heidelberg, 1992, pp 537-543.
4. Kushner BH, O'Reilly RJ, Mandell LR et al. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991; 9: 274-279.
5. Graham-Pole J, Casper J, Elfenbein G et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 152-158.
6. Hartmann O, Benhamou E, Beaujean F et al. Repeated highdose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 1987; 5: 1205-1211.
7. Philip T, Bernard JL, Zucker JM et al.: High-dose chemoradiotherapy with bone marrow transplantation as consolidation on treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age. J Clin Oncol 1987; 5: 266-271.
8. Evans AE, August CS, Kamani N et al. Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: an update. Med Ped Oncol 1994; 23: 323-327.
9. Shuster JJ, Cantor AB, McWilliams N et al. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 1991; 9: 1045-1049.
10. Garaventa A, Ladenstein R, Chauvin F et al. High-dose chemotherapy with autologous bone marrow rescue in advanced stage IV neuroblastoma. Eur J Cancer 1993; 29A: 487-491.
11. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma. Diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
12. Kaplan EL, Meier P. Non-parametric Estimation from Incomplete Observations. McGraw-Hill: New York, 1956.
13. Peto R, McPherson K, Peto J et al. Design and analysis of clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39.
14. Cheung NKV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050-1058.
15. Pinkerton CR. Where next with therapy in advanced neuroblastoma? Br J Cancer 1990; 61: 351-353.
16. Matthay KK, O'Leary MC, Ramsay NK et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer 1995; 31A: 572-575.
17. Ladenstein R, Lasset C, Hartmann O et al. High-dose consolidation chemotherapy in infants with stage 4 neuroblastoma. Eur J Cancer 1993; 29A: 1632.
18. Takeda O, Homma C, Maseki N et al. There may be two tumour suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Cancer 1994; 10: 30-39.
19. Ladenstein R, Lasset C, Hartmann O et al. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. J Clin Oncol 1993; 11: 2330-2341.
20. Brenner MK, Rill DR, Moen RC et al. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-86.
21. Matthay KK, Atkinson JB, Stram DO t al. Pattern of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol 1993; 11: 2226-2233.
22. Matthay KK, Seeger RC, Reynolds CP et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. J Clin Oncol 1994; 12: 2382-2389.
23. Ladenstein R, Lasset C, Hartmann O et al. Comparison of auto versus allografts as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis. A report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14: 37-46.
24. Ladenstein R, Hartmann O, Pinkerton CR. The role of megatherapy with autologous bone marrow rescue in solid tumors of childhood. Ann Oncol 1993; 4: S45-S58.
25. Kremens B, Klingebiel T, Herrmann et al. High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma. Med Ped Oncol 1994; 23: 470-475.
26. 131I MIBG. Adv Neuro Res 1994; 4: 309-317.
27. Mugushima H, Iwata M, Okabe I et al. Autologous bone marrow transplantation in children with advanced neuroblastoma. Cancer 1994; 74: 972-977.
28. Philip T, Ladenstein R, Zucker JM et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993; 67: 119-127.
29. Evans A, Main E, Zier K et al. The effects of gamma interferon on the natural killer and tumor cells of children with neuroblastoma. Cancer 1989; 64: 1383-1387.
30. Donfrancesco A, Deb G, Dominici C et al. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990; 50: 4929-4930.
31. Carreras E, Granena A, Rozman C. Hepatic veno-occlusive disease after bone marrow transplant. Blood Reviews 1993; 7: 43-51.
32. Graham ML, Yeager AM, Leventhal BG et al. Treatment of recurrent and refractory pediatric solid tumors with high-dose busulfan and cyclophosphamide followed by autologous bone marrow rescue. J Clin Oncol 1992; 10: 1857-1864.
33. Corbett R, Pinkerton R, Pritchard J et al. Pilot study of highdose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 1992; 28A: 1324-1328.